Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M210,182Revenue $M58,831Net Margin (%)16.8Z-Score3.3
Enterprise Value $M223,407EPS $3.7Operating Margin %20.1F-Score6
P/E(ttm))23.3Cash Flow Per Share $0Pre-tax Margin (%)19.9Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %2.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %4.5Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-3.0ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %3.1Insider Buy (3m)0ROE % (ttm)13.5Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M2,426ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 86.63-1%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 86.63-1%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 86.63-1%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 86.637%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 86.637%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 86.6312%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 86.6317%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 86.6319%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 86.6319%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 86.6319%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 86.6328%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 86.6328%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 86.6328%Reduce -21.03%33,456
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 86.6340%Add 2.65%48,438,459
NVSKen Fisher 2012-09-30 Buy 0.86%$55.24 - $61.51
($58.49)
$ 86.6348%New holding, 5086362 sh.5,086,362
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 86.6348%Add 3.23%47,187,759
NVSMario Gabelli 2012-03-31 Reduce$53.31 - $58.33
($52.37)
$ 86.6365%Reduce -37.42%11,740
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 86.6365%Sold Out0
NVSJohn Hussman 2012-03-31 Reduce-0.14%$53.31 - $58.33
($52.37)
$ 86.6365%Reduce -22.44%515,000
NVSKen Fisher 2012-03-31 Sold Out -0.13%$53.31 - $58.33
($52.37)
$ 86.6365%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Dodge & Cox 2014-06-3051,102,2192.114.4+10.04%
NVS Ken Fisher 2014-06-305,969,9630.251.1+1.37%
NVS Jean-Marie Eveillard 2014-06-3013,06000
NVS PRIMECAP Management 2014-06-3023,846,2360.982.4-0.7%
NVS Tweedy Browne 2014-06-30288,8250.010.56-0.92%
NVS John Hussman 2014-06-30214,0000.011.5-3.25%
NVS Mario Gabelli 2014-06-3010,24000-4.66%
NVS Irving Kahn 2014-06-3026,36800.35-6.06%
NVS HOTCHKIS & WILEY 2014-06-30649,5190.030.21-71.8%
NVS Lee Ainslie 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15477.53view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Novartis: Ten Years of Solid ROE Jul 31 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 


      More From Other Websites
      Novartis Presents Encouraging Data on Leukemia Candidate Oct 16 2014
      Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with... Oct 15 2014
      Why Teva Pharmaceutical (TEVA) Stock Is Falling Today Oct 15 2014
      Novartis Releases Data on Secukinumab for Plaque Psoriasis Oct 13 2014
      Novartis aims for a bigger share of the global anti-cancer drugs market with a stake in Oxford... Oct 12 2014
      Novartis strikes deal with Oxford BioMedica for cancer treatment Oct 10 2014
      BUZZ-Oxford Biomedica: Signs 3-year deal with Novartis Oct 10 2014
      Oxford Biomedica strikes 'transformational' $90m deal with Novartis Oct 09 2014
      Shareholder group critical as Roche and Novartis chiefs top Swiss pay table Oct 08 2014
      Shareholder group critical as Roche and Novartis chiefs top Swiss pay table Oct 08 2014
      Novartis says three executives to leave after GSK, Lilly deals Oct 08 2014
      Novartis says 3 executives to leave after GSK, Lilly deals Oct 08 2014
      Novartis says 3 executives to leave after GSK, Lilly deals Oct 08 2014
      Novartis Collaborates with Bristol-Myers Squibb Oct 07 2014
      Incyte Receives $60M Milestone Payment Related to Jakavi Oct 06 2014
      Novartis works with Bristol-Myers Squibb to test lung cancer drugs Oct 06 2014
      Novartis works with Bristol-Myers for lung cancer studies Oct 06 2014
      EU OKs Eli Lilly's $5.4B bid for Novartis division Oct 03 2014
      EU OKs Eli Lilly's $5.4B bid for Novartis division Oct 03 2014
      Novartis (NVS) Presents Data on Zykadia and Afinitor Oct 02 2014
      Novartis ordered to face U.S. lawsuit over doctor kickbacks Sep 30 2014
      Novartis Gives Updates on Signifor LAR and Secukinumab Sep 29 2014
      Multiple Sclerosis Drugs Could Transform Market Again Sep 26 2014
      Ford revs up expansion plans Sep 25 2014
      Novartis Says Psoriasis Drug Met End-Goal of Arthritis Studies Sep 25 2014
      Could European Funds Offer An Opportunity Now? Sep 23 2014
      Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published Sep 22 2014
      [video] Prologis, Wells Fargo Still Wise Investments Says Fund Manager Sep 22 2014
      IPO Stock Watch: Biotech ProQR Rises In IPO Debut Sep 18 2014
      The Market's Thorns, Roses, and All Time Highs... Sep 17 2014
      Novartis Japan admits concealing drug side effects Sep 01 2014
      Novartis Japan admits concealing drug side effects Sep 01 2014
      Tests promise 'blockbuster' new heart failure drug Aug 31 2014
      Tests promise 'blockbuster' new heart failure drug Aug 30 2014
      Novartis loses new bid to dismiss U.S. lawsuit over kickbacks Aug 07 2014
      Novartis cites momentum in 3 percent profit rise Jul 17 2014
      Drugmaker Novartis to eke out more cost savings to lift margins Jul 17 2014
      Novartis and Google to develop 'smart' contact lens Jul 15 2014
      Novartis and Google to develop 'smart' contact lens Jul 15 2014
      Novartis hopes to commercialise "smart lens" within 5 years Jul 15 2014
      Novartis faces criminal charge in Japan Jul 01 2014
      Novartis: drug costs can come down with fewer 'fails' Jun 28 2014
      Novartis, Pfizer seek U.S. approval of meningitis vaccines Jun 17 2014
      Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero® to help protect... Jun 17 2014
      Tokyo prosecutors raid Novartis Japan unit over clinical data probe Jun 11 2014
      Novartis appoints Merck executive as oncology chief Jun 01 2014
      Novartis appoints Merck executive as oncology chief Jun 01 2014
      Italy seeks 1.2 bn euros in damages from Roche, Novartis May 28 2014
      Italy seeks anti-trust compensation from Roche, Novartis, Pfizer May 28 2014
      Italy seeks 1.2 bn euros in damages from Roche, Novartis May 28 2014
      Novartis, Sun Pharma settle dispute over generic Gleevec May 15 2014
      Novartis, Sun Pharma settle dispute over generic Gleevec May 15 2014
      First Myelofibrosis Medication for Life-threatening Blood Cancer Approved in Singapore May 14 2014
      Novartis lung drug not inferior to GSK's Seretide, study shows Apr 25 2014
      New drug sales help boost Novartis Q1 profit Apr 24 2014
      Pharma giant Novartis sees net profit jump 24% Apr 24 2014
      Novartis sales miss forecast as readies overhaul Apr 24 2014
      Novartis reports Q1 profit up on divestitures Apr 24 2014
      Pharma giant Novartis sees net profit jump 24% Apr 23 2014
      Novartis-GSK asset swap offers template for pharma and beyond Apr 23 2014
      Novartis, Valeant bids herald new deal-making era for pharma Apr 22 2014
      Novartis, Valeant bids herald new deal-making era for pharma Apr 22 2014
      Novartis, Valeant bids herald new deal-making era for pharma Apr 22 2014
      Novartis and GSK trade assets as pharma industry reshapes Apr 22 2014
      Shake-up in pharma world as Novartis, GSK announce mega-deals Apr 22 2014
      Novartis revamps pharma world with mega-deals with GSK, Eli Lilly Apr 22 2014
      GSK unveils major Novartis deal amid pharma bonanza Apr 22 2014
      Novartis reshapes business via deals with GSK and Lilly Apr 22 2014
      Novartis, GSK reveal huge deals in global healthcare markets Apr 22 2014
      GSK, Novartis unveil major healthcare revamp Apr 22 2014
      Shake-up in pharma world as Novartis, GSK announce mega-deals Apr 22 2014
      Novartis exchanges assets with Glaxosmithkline Apr 22 2014
      Novartis revamps pharma world with mega-deals with GSK, Eli Lilly Apr 21 2014
      Novartis, GSK reveal huge deals in global healthcare markets Apr 21 2014
      GSK, Novartis unveil major healthcare revamp Apr 21 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK